Assignee
UNIQURE BIOPHARMA B V
NL·4 granted patents·22 pending applications·10 citations·filing 2009–2025
Top patents by PatentIndex Score
26 records- 0190US9982248B2Factor IX polypeptide mutant, its uses and method for its productionUNIQURE BIOPHARMA B V·Filed 2017·Granted May 29, 2018·7 cites·20 claims
- 0288US10465180B2Factor IX polypeptide mutant, its uses and method for its productionUNIQURE BIOPHARMA B V·Filed 2018·Granted Nov 5, 2019·3 cites·6 claims
- 0376USRE50288EFactor IX polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2009·Granted Feb 4, 2025·0 cites·21 claims
- 0476US2022090042A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2021·Application pending·0 cites
- 0575US2022002702A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2021·Application pending·0 cites
- 0673US2025179462A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2025·Application pending·0 cites
- 0773US2021214704A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2021·Application pending·0 cites
- 0873US2021238573A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2021·Application pending·0 cites
- 0968US2020190498A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2019·Application pending·0 cites
- 1068US2020199564A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2020·Application pending·0 cites
- 1168US2020231958A1Factor ix polypeptide mutant, its uses and a method for its productionUNIQURE BIOPHARMA B V·Filed 2019·Application pending·0 cites
- 1263US2024293577A1Methods and means for the prevention and/or treatment of hemophilic arthropathy in hemophiliaUNIQURE BIOPHARMA B V·Filed 2023·Application pending·0 cites
- 1363US2025223590A1Nucleic acid regulation of ApoEUNIQURE BIOPHARMA B V·Filed 2023·Application pending·0 cites
- 1461US2024287545A1Improved lysis proceduresUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 1561US2026061079A1BBB interacting capsidsUNIQURE BIOPHARMA B V·Filed 2025·Application pending·0 cites
- 1661US2025382611A1Gene constructs for silencing alpha-synuclein and uses thereofUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 1760US2025230437A1Novel systems for nucleic acid regulationUNIQURE BIOPHARMA B V·Filed 2023·Application pending·0 cites
- 1860US2025297252A1Nucleic acid regulation of SNCAUNIQURE BIOPHARMA B V·Filed 2023·Application pending·0 cites
- 1960US2024240206A1Insect cell production of parvoviral vectors with modified capsid proteinsUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 2057US2023159951A1Dual bifunctional vectors for aav productionUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 2156US2024374755A1Adeno-associated virus vectors modified to bind High-Density LipoproteinUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 2255US12544459B2Methods and means for the prevention and/or treatment of hemophilic arthropathy in hemophiliaUNIQURE BIOPHARMA B V·Filed 2025·Granted Feb 10, 2026·0 cites·17 claims
- 2355US2025297278A1Insect cell-produced high potency AAV vectors with CNS-tropismUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 2454US2024181082A1Methods and means for the prevention and/or treatment of hemophilic arthropathy in hemophiliaUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 2554US2023265381A1Novel cell lineUNIQURE BIOPHARMA B V·Filed 2022·Application pending·0 cites
- 2650US2024200094A1Methods for producing single insect cell clonesUNIQURE BIOPHARMA B V·Filed 2023·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when UNIQURE BIOPHARMA B V files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →